Merck, Takeda join forces to develop anti-cancer treatment


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/afp/20050929/hl_afp/germanyjapanpharma"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/afp/20050929/capt.sge.mnx71.290905171204.photo00.photo.default-226x165.jpg?x=130&y=94&sig=xmS9V2xd2GIsqwXX2TJHYg--" align="left" height="94" width="130" alt="German pharmaceuticals specialist Merck said Thursday it is teaming up with Japanese rival Takeda to jointly develop and market Merck's Matuzumab cancer treatment, currently in Phase II of clinical trials.(Merck)" border="0" /></a>AFP - German pharmaceuticals specialist Merck said it is teaming up with Japanese rival Takeda to jointly develop and market Merck's Matuzumab cancer treatment, currently in Phase II of clinical trials.</p><br clear=all>